HC Wainwright Issues Negative Estimate for DRUG Earnings
Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
What is HC Wainwright’s Forecast for LPTH FY2025 Earnings?
HC Wainwright dropped their FY2025 earnings estimates for shares of LightPath Technologies in a report released on Tuesday, February 18th. HC Wainwright analyst S. Buck now expects that the technology ...
H.C. Wainwright says SEC plan to dismiss suit lifts ‘major overhang’ on Coinbase
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright Sticks to Its Hold Rating for Biotricity (BTCY)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
Hosted on MSN16d
HC Wainwright & Co. Initiates Coverage of Harrow (HROW) with Buy Recommendation
Fintel reports that on February 6, 2025, HC Wainwright & Co. initiated coverage of Harrow (NasdaqGM:HROW) with a Buy recommendation. Analyst Price Forecast Suggests 97.63% Upside As of January 29 ...
Investing18d
H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock
On Tuesday, H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst ...
Investing18d
H.C. Wainwright maintains buy on Northern Dynasty stock
Tuesday, H.C. Wainwright reaffirmed its Buy rating on Northern Dynasty Minerals (NYSE:NAK) with a steady price target of $1.30, representing significant upside from the current trading price of $0.65.
Nasdaq19d
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (BRSE:1CG) with Buy Recommendation
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...